- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity | 1 | Seeking Alpha | ||
| Do | Earnings Call: Cibus verfehlt Umsatzprognose für Q2 2026 - Aktie bricht nachbörslich um 16 % ein | 1 | Investing.com Deutsch | ||
| Do | Transcript: Cibus Q2 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| CIBUS Aktie jetzt für 0€ handeln | |||||
| Do | Cibus GAAP EPS of -$0.29 misses by $0.10, revenue of $0.99M misses by $0.71M | 1 | Seeking Alpha | ||
| Do | Cibus, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Do | Cibus, Inc.: Cibus Reports Second Quarter Financial Results and Provides Business Update | 141 | GlobeNewswire (Europe) | Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly... ► Artikel lesen | |
| Di | Lendlease sells half stake in two regional shopping centres to Cbus | - | Inside Retail | ||
| 14.07. | Cibus (CBUS) Welcomes Landmark EU Crop Breeding Decision | - | Insider Monkey | ||
| 23.06. | Cibus, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.06. | Cibus, Inc.: Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus | 1 | GlobeNewswire (USA) | ||
| 09.06. | Cibus names board member Craig Wichner as new CEO | 1 | Seeking Alpha | ||
| 09.06. | Cibus appoints Craig Wichner as chief executive officer | 3 | Investing.com | ||
| 09.06. | Cibus, Inc.: Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation | 223 | GlobeNewswire (Europe) | SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company" or "Cibus"), a leading agricultural technology company that develops and licenses plant traits to seed companies... ► Artikel lesen | |
| 05.06. | Cibus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Cibus outlines runway into late Q1 2027 while shifting U.S. rice launch to 2029 | 3 | Seeking Alpha | ||
| 14.05. | Cibus Q1 2026: Deutlich geringerer Verlust und verbesserte Kosteneffizienz | 1 | Investing.com Deutsch | ||
| 14.05. | Cibus Q1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 14.05. | Cibus, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | Cibus GAAP EPS of -$0.33 misses by $0.06, revenue of $1.68M beats by $0.06M | 2 | Seeking Alpha | ||
| 14.05. | Cibus, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | 0,00 % | Moderna-Aktie: Plötzlich deutlich besser als BioNTech | Die Moderna-Aktie überrascht die Börse rund um das Wochenende mit einem neuen Höhenflug. Nachdem der Kurs des Biotech-Konzerns bereits am Freitag um +10% in die Höhe geschossen ist, setzt sich die gute... ► Artikel lesen | |
| EVOTEC | 3,446 | 0,00 % | Evotec-Aktie: Das ist ein wichtiger Baustein für die Kurserholung | Die Evotec-Aktie kam seit dem Kursabsturz Anfang Juli nicht mehr auf die Beine und bewegt sich innerhalb einer Range von 3,45 bis 3,55 €. Am Montag notiert sie aktuell bei 3,53 €. Momentan leidet sie... ► Artikel lesen | |
| MODERNA | 54,61 | -0,20 % | Pharma and Biotech Stocks in the Spotlight: Moderna, BioNxt Solutions, and Eli Lilly | ||
| NOVAVAX | 6,950 | -0,14 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| ILLUMINA | 165,24 | +0,16 % | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,640 | +1,69 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| BRAIN BIOTECH | 2,740 | -2,49 % | Brain Biotech: Sven K. Weber wird neuer Vorstandsvorsitzender | Der Aufsichtsrat der Brain Biotech AG hat Sven K. Weber zum 1. Oktober 2026 für drei Jahre zum neuen Vorstandsvorsitzenden bestellt. Der 44-Jährige war seit 2011 in verschiedenen Führungspositionen... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | +2,45 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,232 | -2,28 % | 'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery | ||
| IBIO | 1,190 | -4,11 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Deutsche Bank cuts Atai stock rating on Lilly acquisition terms | ||
| TME PHARMA | 0,061 | 0,00 % | TME Pharma NV: Minutes of the TME Pharma Annual General Meeting | Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,090 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 | King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based... ► Artikel lesen | |
| CELLECTIS | 2,670 | 0,00 % | Cellectis Reports Financial Results for the Second Quarter 2026 | Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim... ► Artikel lesen | |
| MACROGENICS | 3,360 | -8,70 % | MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program | ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment... ► Artikel lesen |
CIBUS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,775 Euro und damit +0,28 % im Plus. Die Dividendendrendite beträgt aktuell +5,56 % (berechnet anhand der Ausschüttung von 0,10 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CIBUS INC finden Sie auf Wallstreet Online.